CN102766142A - 有效作为蛋白激酶抑制剂的内酰胺化合物 - Google Patents

Info

Publication number

CN102766142A

CN102766142A CN2012102393383A CN201210239338A CN102766142A CN 102766142 A CN102766142 A CN 102766142A CN 2012102393383 A CN2012102393383 A CN 2012102393383A CN 201210239338 A CN201210239338 A CN 201210239338A CN 102766142 A CN102766142 A CN 102766142A

Authority

CN

China

Prior art keywords

group

aliphatic group

ring

optional

benzo

Prior art date

2004-10-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
• 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
• -1 Lactam compounds Chemical class 0.000 title description 108
• 238000000034 method Methods 0.000 claims abstract description 249
• 150000001875 compounds Chemical class 0.000 claims abstract description 184
• 239000000203 mixture Substances 0.000 claims abstract description 73
• 150000003839 salts Chemical class 0.000 claims abstract description 27
• 238000011282 treatment Methods 0.000 claims abstract description 24
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
• 125000003118 aryl group Chemical group 0.000 claims description 83
• 125000001072 heteroaryl group Chemical group 0.000 claims description 81
• 125000001931 aliphatic group Chemical group 0.000 claims description 71
• 125000000623 heterocyclic group Chemical group 0.000 claims description 65
• 229910052739 hydrogen Inorganic materials 0.000 claims description 65
• 239000001257 hydrogen Substances 0.000 claims description 63
• 206010028980 Neoplasm Diseases 0.000 claims description 61
• 125000002947 alkylene group Chemical group 0.000 claims description 53
• 229910052799 carbon Inorganic materials 0.000 claims description 42
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
• 229910052736 halogen Inorganic materials 0.000 claims description 35
• 108091000080 Phosphotransferase Proteins 0.000 claims description 34
• 102000020233 phosphotransferase Human genes 0.000 claims description 34
• 201000011510 cancer Diseases 0.000 claims description 32
• 239000003814 drug Substances 0.000 claims description 32
• 229910052757 nitrogen Inorganic materials 0.000 claims description 32
• 125000004429 atom Chemical group 0.000 claims description 31
• 239000005441 aurora Substances 0.000 claims description 31
• 125000002723 alicyclic group Chemical group 0.000 claims description 29
• 229910052717 sulfur Inorganic materials 0.000 claims description 29
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 28
• 229910052760 oxygen Inorganic materials 0.000 claims description 28
• 101150050673 CHK1 gene Proteins 0.000 claims description 25
• 230000000694 effects Effects 0.000 claims description 24
• 150000002367 halogens Chemical class 0.000 claims description 24
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 23
• 150000002431 hydrogen Chemical class 0.000 claims description 23
• 229910052731 fluorine Inorganic materials 0.000 claims description 21
• 239000011737 fluorine Substances 0.000 claims description 17
• 239000003153 chemical reaction reagent Substances 0.000 claims description 15
• 230000004927 fusion Effects 0.000 claims description 15
• 125000006574 non-aromatic ring group Chemical group 0.000 claims description 15
• 125000003107 substituted aryl group Chemical group 0.000 claims description 14
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 13
• 125000002837 carbocyclic group Chemical group 0.000 claims description 13
• 125000004432 carbon atom Chemical group C* 0.000 claims description 13
• 125000001424 substituent group Chemical group 0.000 claims description 12
• 230000015572 biosynthetic process Effects 0.000 claims description 9
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 8
• 238000003780 insertion Methods 0.000 claims description 8
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 7
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 5
• 125000005605 benzo group Chemical group 0.000 claims description 4
• 238000001959 radiotherapy Methods 0.000 claims description 4
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
• 150000004866 oxadiazoles Chemical class 0.000 claims description 3
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
• 150000004867 thiadiazoles Chemical class 0.000 claims description 3
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
• 238000002512 chemotherapy Methods 0.000 claims description 2
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
• 101710112752 Cytotoxin Proteins 0.000 claims 1
• 231100000599 cytotoxic agent Toxicity 0.000 claims 1
• 239000002619 cytotoxin Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
• 201000010099 disease Diseases 0.000 abstract description 12
• 210000004027 cell Anatomy 0.000 description 76
• 239000000243 solution Substances 0.000 description 67
• 239000002585 base Substances 0.000 description 59
• ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 55
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
• 230000008859 change Effects 0.000 description 51
• 239000003795 chemical substances by application Substances 0.000 description 41
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
• 239000011541 reaction mixture Substances 0.000 description 37
• 238000012360 testing method Methods 0.000 description 37
• 239000003921 oil Substances 0.000 description 33
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 31
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 30
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
• 238000006243 chemical reaction Methods 0.000 description 29
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 28
• 239000002512 suppressor factor Substances 0.000 description 28
• 102000001253 Protein Kinase Human genes 0.000 description 27
• 108060006633 protein kinase Proteins 0.000 description 27
• 239000000460 chlorine Substances 0.000 description 25
• 238000005406 washing Methods 0.000 description 25
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
• 239000007787 solid Substances 0.000 description 23
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
• 150000001412 amines Chemical class 0.000 description 22
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
• 238000000746 purification Methods 0.000 description 20
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 19
• 125000000217 alkyl group Chemical group 0.000 description 19
• 239000012141 concentrate Substances 0.000 description 19
• 150000001721 carbon Chemical group 0.000 description 18
• 238000004587 chromatography analysis Methods 0.000 description 18
• 238000001035 drying Methods 0.000 description 18
• 235000019441 ethanol Nutrition 0.000 description 18
• 125000004494 ethyl ester group Chemical group 0.000 description 18
• 239000003112 inhibitor Substances 0.000 description 18
• 229910002651 NO3 Inorganic materials 0.000 description 17
• 235000008504 concentrate Nutrition 0.000 description 16
• 238000003756 stirring Methods 0.000 description 16
• 239000012043 crude product Substances 0.000 description 15
• 150000004702 methyl esters Chemical class 0.000 description 15
• 230000000394 mitotic effect Effects 0.000 description 15
• 235000019198 oils Nutrition 0.000 description 15
• 239000002253 acid Substances 0.000 description 14
• 125000004093 cyano group Chemical group *C#N 0.000 description 14
• 239000007788 liquid Substances 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 230000008569 process Effects 0.000 description 14
• 239000011347 resin Substances 0.000 description 14
• 229920005989 resin Polymers 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 13
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 230000006378 damage Effects 0.000 description 12
• 150000002148 esters Chemical class 0.000 description 12
• SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 11
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 230000001404 mediated effect Effects 0.000 description 10
• 239000000843 powder Substances 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• SXTSBZBQQRIYCU-UHFFFAOYSA-N 4-guanidinobenzoic acid Chemical compound NC(=N)NC1=CC=C(C(O)=O)C=C1 SXTSBZBQQRIYCU-UHFFFAOYSA-N 0.000 description 9
• 102000003989 Aurora kinases Human genes 0.000 description 9
• 108090000433 Aurora kinases Proteins 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 230000004663 cell proliferation Effects 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 238000006911 enzymatic reaction Methods 0.000 description 9
• 238000001914 filtration Methods 0.000 description 9
• 239000000758 substrate Substances 0.000 description 9
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
• 0 CC(N*)=N*=C(C1(*(*)(C2C3C4C2C4)C2CC=CCC2)*=*1)C3=* Chemical compound CC(N*)=N*=C(C1(*(*)(C2C3C4C2C4)C2CC=CCC2)*=*1)C3=* 0.000 description 8
• 229910052693 Europium Inorganic materials 0.000 description 8
• QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 239000003513 alkali Substances 0.000 description 8
• 150000001408 amides Chemical class 0.000 description 8
• 238000010511 deprotection reaction Methods 0.000 description 8
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 8
• 239000000706 filtrate Substances 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 238000010438 heat treatment Methods 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 229940095102 methyl benzoate Drugs 0.000 description 8
• 238000001953 recrystallisation Methods 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
• 150000001299 aldehydes Chemical class 0.000 description 7
• 239000007864 aqueous solution Substances 0.000 description 7
• 230000022131 cell cycle Effects 0.000 description 7
• 238000010790 dilution Methods 0.000 description 7
• 239000012895 dilution Substances 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 125000000524 functional group Chemical group 0.000 description 7
• 239000012044 organic layer Substances 0.000 description 7
• 230000026731 phosphorylation Effects 0.000 description 7
• 238000006366 phosphorylation reaction Methods 0.000 description 7
• 125000004193 piperazinyl group Chemical group 0.000 description 7
• 125000005936 piperidyl group Chemical group 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 150000003254 radicals Chemical class 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 230000000699 topical effect Effects 0.000 description 7
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 241000238631 Hexapoda Species 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 230000000973 chemotherapeutic effect Effects 0.000 description 6
• 238000005859 coupling reaction Methods 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 230000005855 radiation Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 125000002769 thiazolinyl group Chemical group 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 239000003005 anticarcinogenic agent Substances 0.000 description 5
• 125000003710 aryl alkyl group Chemical group 0.000 description 5
• 230000033228 biological regulation Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 125000002883 imidazolyl group Chemical group 0.000 description 5
• 125000005956 isoquinolyl group Chemical group 0.000 description 5
• 229910052763 palladium Inorganic materials 0.000 description 5
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 5
• 108010056274 polo-like kinase 1 Proteins 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 125000003226 pyrazolyl group Chemical group 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 238000006722 reduction reaction Methods 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 150000003457 sulfones Chemical class 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
• 238000005160 1H NMR spectroscopy Methods 0.000 description 4
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 239000004215 Carbon black (E152) Substances 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
• KFRKUTMNFATRGW-UHFFFAOYSA-N IC1=CC=C(C=C1)C(=O)O.C(C)(=O)NC1=C(C=CC=C1O)[As](O)(O)=O Chemical compound IC1=CC=C(C=C1)C(=O)O.C(C)(=O)NC1=C(C=CC=C1O)[As](O)(O)=O KFRKUTMNFATRGW-UHFFFAOYSA-N 0.000 description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 230000005875 antibody response Effects 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000004440 column chromatography Methods 0.000 description 4
• 238000010828 elution Methods 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 150000002240 furans Chemical class 0.000 description 4
• 125000005842 heteroatom Chemical group 0.000 description 4
• 238000004896 high resolution mass spectrometry Methods 0.000 description 4
• 229930195733 hydrocarbon Natural products 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 4
• 150000002825 nitriles Chemical class 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 125000000714 pyrimidinyl group Chemical group 0.000 description 4
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
• 239000002994 raw material Substances 0.000 description 4
• 238000006268 reductive amination reaction Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 230000001954 sterilising effect Effects 0.000 description 4
• 125000000547 substituted alkyl group Chemical group 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 239000011782 vitamin Substances 0.000 description 4
• 229940088594 vitamin Drugs 0.000 description 4
• 235000013343 vitamin Nutrition 0.000 description 4
• 229930003231 vitamin Natural products 0.000 description 4
• 150000003722 vitamin derivatives Chemical class 0.000 description 4
• 229910052727 yttrium Inorganic materials 0.000 description 4
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 3
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
• 239000005695 Ammonium acetate Substances 0.000 description 3
• 241000208340 Araliaceae Species 0.000 description 3
• 102000003916 Arrestin Human genes 0.000 description 3
• 108090000328 Arrestin Proteins 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
• 235000003140 Panax quinquefolius Nutrition 0.000 description 3
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 229910000564 Raney nickel Inorganic materials 0.000 description 3
• 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 3
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
• 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
• 235000019257 ammonium acetate Nutrition 0.000 description 3
• 229940043376 ammonium acetate Drugs 0.000 description 3
• 230000001028 anti-proliverative effect Effects 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 229910052786 argon Inorganic materials 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000011097 chromatography purification Methods 0.000 description 3
• 201000010989 colorectal carcinoma Diseases 0.000 description 3
• 238000007872 degassing Methods 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• 238000005227 gel permeation chromatography Methods 0.000 description 3
• 235000008434 ginseng Nutrition 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000003128 head Anatomy 0.000 description 3
• 125000004475 heteroaralkyl group Chemical group 0.000 description 3
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
• 238000009413 insulation Methods 0.000 description 3
• 238000000021 kinase assay Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 125000002757 morpholinyl group Chemical group 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 150000002829 nitrogen Chemical group 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical group N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 3
• 125000002971 oxazolyl group Chemical group 0.000 description 3
• 239000012286 potassium permanganate Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 125000003373 pyrazinyl group Chemical group 0.000 description 3
• 150000003233 pyrroles Chemical class 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000007789 sealing Methods 0.000 description 3
• 229910052710 silicon Inorganic materials 0.000 description 3
• 239000010703 silicon Substances 0.000 description 3
• 238000004659 sterilization and disinfection Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 125000001544 thienyl group Chemical group 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 125000001425 triazolyl group Chemical group 0.000 description 3
• CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 239000003643 water by type Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• CHAFZGUGLLKKQE-UHFFFAOYSA-N 2-(3,5-dimethylphenyl)guanidine Chemical compound CC1=CC(C)=CC(NC(N)=N)=C1 CHAFZGUGLLKKQE-UHFFFAOYSA-N 0.000 description 2
• YIZRGZCXUWSHLN-UHFFFAOYSA-N 2-(3-aminophenyl)acetonitrile Chemical compound NC1=CC=CC(CC#N)=C1 YIZRGZCXUWSHLN-UHFFFAOYSA-N 0.000 description 2
• PYNDWPFZDQONDV-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1C PYNDWPFZDQONDV-UHFFFAOYSA-N 0.000 description 2
• DOLQYFPDPKPQSS-UHFFFAOYSA-N 3,4-dimethylaniline Chemical compound CC1=CC=C(N)C=C1C DOLQYFPDPKPQSS-UHFFFAOYSA-N 0.000 description 2
• MKARNSWMMBGSHX-UHFFFAOYSA-N 3,5-dimethylaniline Chemical compound CC1=CC(C)=CC(N)=C1 MKARNSWMMBGSHX-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical class ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 2
• XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 2
• IOEHXNCBPIBDBZ-UHFFFAOYSA-N 5-iodo-2-methylaniline Chemical compound CC1=CC=C(I)C=C1N IOEHXNCBPIBDBZ-UHFFFAOYSA-N 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
• 208000019838 Blood disease Diseases 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
• 230000004543 DNA replication Effects 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• 208000009527 Refractory anemia Diseases 0.000 description 2
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
• 239000012317 TBTU Substances 0.000 description 2
• DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 150000001350 alkyl halides Chemical class 0.000 description 2
• 239000003098 androgen Substances 0.000 description 2
• 150000001448 anilines Chemical class 0.000 description 2
• 230000002927 anti-mitotic effect Effects 0.000 description 2
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 229960004217 benzyl alcohol Drugs 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical group CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 238000006555 catalytic reaction Methods 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 235000009508 confectionery Nutrition 0.000 description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 238000013016 damping Methods 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• MJFQUUWPZOGYQT-UHFFFAOYSA-O diaminomethylideneazanium;nitrate Chemical compound NC(N)=[NH2+].[O-][N+]([O-])=O MJFQUUWPZOGYQT-UHFFFAOYSA-O 0.000 description 2
• TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical group C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 150000002081 enamines Chemical class 0.000 description 2
• 235000019439 ethyl acetate Nutrition 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 230000004992 fission Effects 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 208000014951 hematologic disease Diseases 0.000 description 2
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 239000000138 intercalating agent Substances 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 239000007791 liquid phase Substances 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
• FSNRVHNXSYBHSI-UHFFFAOYSA-N methyl 2-amino-4-iodobenzoate Chemical class COC(=O)C1=CC=C(I)C=C1N FSNRVHNXSYBHSI-UHFFFAOYSA-N 0.000 description 2
• NNXVARLKWUFGGG-UHFFFAOYSA-N methyl 2-amino-5-iodobenzoate Chemical class COC(=O)C1=CC(I)=CC=C1N NNXVARLKWUFGGG-UHFFFAOYSA-N 0.000 description 2
• VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
• LSRZBUBQOBXWPK-UHFFFAOYSA-N n-(5-iodo-2-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC(I)=CC=C1C LSRZBUBQOBXWPK-UHFFFAOYSA-N 0.000 description 2
• 210000005170 neoplastic cell Anatomy 0.000 description 2
• 229960003512 nicotinic acid Drugs 0.000 description 2
• 235000001968 nicotinic acid Nutrition 0.000 description 2
• 239000011664 nicotinic acid Substances 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 231100000956 nontoxicity Toxicity 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 238000011580 nude mouse model Methods 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
• 229920001451 polypropylene glycol Polymers 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 235000015320 potassium carbonate Nutrition 0.000 description 2
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• FWLKYEAOOIPJRL-UHFFFAOYSA-N prop-1-yn-1-ol Chemical compound CC#CO FWLKYEAOOIPJRL-UHFFFAOYSA-N 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• 125000005493 quinolyl group Chemical group 0.000 description 2
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
• 230000022983 regulation of cell cycle Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 201000000498 stomach carcinoma Diseases 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 125000001113 thiadiazolyl group Chemical group 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• 150000003556 thioamides Chemical class 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 2
• 229960000641 zorubicin Drugs 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
• UVQYBUYGFBXQGO-SCSAIBSYSA-N (2r)-4-methoxy-2-methyl-4-oxobutanoic acid Chemical class COC(=O)C[C@@H](C)C(O)=O UVQYBUYGFBXQGO-SCSAIBSYSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• BZZXQZOBAUXLHZ-UHFFFAOYSA-N (c-methylsulfanylcarbonimidoyl)azanium;sulfate Chemical compound CSC(N)=N.CSC(N)=N.OS(O)(=O)=O BZZXQZOBAUXLHZ-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• VJQCNCOGZPSOQZ-UHFFFAOYSA-N 1-Methylguanidine hydrochloride Chemical compound [Cl-].C[NH2+]C(N)=N VJQCNCOGZPSOQZ-UHFFFAOYSA-N 0.000 description 1
• QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical compound CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• SOBSYGGSAKHFRZ-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)guanidine Chemical compound O1CCOC2=CC(NC(=N)N)=CC=C21 SOBSYGGSAKHFRZ-UHFFFAOYSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• HKPHVFFQXHMOHX-UHFFFAOYSA-N 2-(2-chlorophenyl)guanidine Chemical compound NC(=N)NC1=CC=CC=C1Cl HKPHVFFQXHMOHX-UHFFFAOYSA-N 0.000 description 1
• CDBWVYYYKYLWIW-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)guanidine Chemical compound COC1=CC(NC(N)=N)=CC(OC)=C1 CDBWVYYYKYLWIW-UHFFFAOYSA-N 0.000 description 1
• FNUKLSVGSFFSLI-UHFFFAOYSA-N 2-(3-aminophenyl)ethanol Chemical compound NC1=CC=CC(CCO)=C1 FNUKLSVGSFFSLI-UHFFFAOYSA-N 0.000 description 1
• DWLMIHRZURMFAQ-UHFFFAOYSA-N 2-(3-chlorophenyl)guanidine Chemical compound NC(N)=NC1=CC=CC(Cl)=C1 DWLMIHRZURMFAQ-UHFFFAOYSA-N 0.000 description 1
• VKJFNTIDNIZFDD-UHFFFAOYSA-N 2-(3-iodophenyl)guanidine Chemical compound NC(=N)NC1=CC=CC(I)=C1 VKJFNTIDNIZFDD-UHFFFAOYSA-N 0.000 description 1
• WAVKEPUFQMUGBP-UHFFFAOYSA-N 2-(3-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=CC(CC#N)=C1 WAVKEPUFQMUGBP-UHFFFAOYSA-N 0.000 description 1
• ZSJNJAJDBNFVCA-UHFFFAOYSA-N 2-(4-chlorophenyl)guanidine Chemical compound NC(=N)NC1=CC=C(Cl)C=C1 ZSJNJAJDBNFVCA-UHFFFAOYSA-N 0.000 description 1
• JMWQDIKJRCJGMY-UHFFFAOYSA-N 2-(4-iodophenyl)guanidine Chemical compound NC(=N)NC1=CC=C(I)C=C1 JMWQDIKJRCJGMY-UHFFFAOYSA-N 0.000 description 1
• UMKSAURFQFUULT-UHFFFAOYSA-N 2-Amino-5-methoxybenzoic acid Chemical compound COC1=CC=C(N)C(C(O)=O)=C1 UMKSAURFQFUULT-UHFFFAOYSA-N 0.000 description 1
• WQPOSQDIXGOFCT-UHFFFAOYSA-N 2-[(3,4-dimethoxyphenyl)methyl]guanidine Chemical compound COC1=CC=C(CN=C(N)N)C=C1OC WQPOSQDIXGOFCT-UHFFFAOYSA-N 0.000 description 1
• QUJJXJNCDPREGS-UHFFFAOYSA-N 2-[3-(2-hydroxyethyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=CC(CCO)=C1 QUJJXJNCDPREGS-UHFFFAOYSA-N 0.000 description 1
• QBEKIHWNLZKUIK-UHFFFAOYSA-N 2-[3-(hydroxymethyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=CC(CO)=C1 QBEKIHWNLZKUIK-UHFFFAOYSA-N 0.000 description 1
• PZZOEXPDTYIBPI-UHFFFAOYSA-N 2-[[2-(4-hydroxyphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1=CC(O)=CC=C1CCNCC1C(=O)C2=CC=CC=C2CC1 PZZOEXPDTYIBPI-UHFFFAOYSA-N 0.000 description 1
• JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 1
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
• KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical compound NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 1
• FMHJHVYHYAHRNS-UHFFFAOYSA-N 2-cyclohexa-1,5-dien-1-ylguanidine Chemical compound C1(=CCCC=C1)NC(=N)N FMHJHVYHYAHRNS-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-Dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 1
• STUCMBRFCQKITK-UHFFFAOYSA-N 3-(diaminomethylideneamino)benzoic acid Chemical compound NC(N)=NC1=CC=CC(C(O)=O)=C1 STUCMBRFCQKITK-UHFFFAOYSA-N 0.000 description 1
• XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
• NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
• FFCSRWGYGMRBGD-UHFFFAOYSA-N 3-iodoaniline Chemical compound NC1=CC=CC(I)=C1 FFCSRWGYGMRBGD-UHFFFAOYSA-N 0.000 description 1
• UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
• JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
• FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• ZYKVRFMMRAPHAZ-UHFFFAOYSA-N 7-fluoro-3 Chemical compound C1S(=O)(=O)CC(C=2)=CC(F)=CC=2CS(=O)(=O)CC2=CC=C1C=C2 ZYKVRFMMRAPHAZ-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
• 108010013043 Acetylesterase Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical class NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 108090000461 Aurora Kinase A Proteins 0.000 description 1
• 102100032311 Aurora kinase A Human genes 0.000 description 1
• 102100032306 Aurora kinase B Human genes 0.000 description 1
• 108090000749 Aurora kinase B Proteins 0.000 description 1
• 102100026630 Aurora kinase C Human genes 0.000 description 1
• 108090000805 Aurora kinase C Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• RODDYDSLFDHBOG-UHFFFAOYSA-N C#CCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound C#CCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 RODDYDSLFDHBOG-UHFFFAOYSA-N 0.000 description 1
• VFSFCYAQBIPUSL-UHFFFAOYSA-N C(C1)C1c1ccccc1 Chemical compound C(C1)C1c1ccccc1 VFSFCYAQBIPUSL-UHFFFAOYSA-N 0.000 description 1
• YDNVMVAJGKTAHO-UHFFFAOYSA-N CC(C)(C)CCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound CC(C)(C)CCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 YDNVMVAJGKTAHO-UHFFFAOYSA-N 0.000 description 1
• NTFZHFGLYBTEGG-UHFFFAOYSA-N CC(C)(C)OC(NCC#Cc(cc1N2)ccc1-c1nc(Nc(cc3)cc(OC)c3OC)ncc1CC2=O)=O Chemical compound CC(C)(C)OC(NCC#Cc(cc1N2)ccc1-c1nc(Nc(cc3)cc(OC)c3OC)ncc1CC2=O)=O NTFZHFGLYBTEGG-UHFFFAOYSA-N 0.000 description 1
• QVNUJZZYRVFDCU-UHFFFAOYSA-N CC(C)(CNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)CN(C)C Chemical compound CC(C)(CNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)CN(C)C QVNUJZZYRVFDCU-UHFFFAOYSA-N 0.000 description 1
• DTIGQAXEOHCFKX-UHFFFAOYSA-N CC(C)NS(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)(=O)=O Chemical compound CC(C)NS(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)(=O)=O DTIGQAXEOHCFKX-UHFFFAOYSA-N 0.000 description 1
• HMLGVSZGRGLPCV-UHFFFAOYSA-N CC(C)OCCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound CC(C)OCCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 HMLGVSZGRGLPCV-UHFFFAOYSA-N 0.000 description 1
• BOKJIUOJQZULSG-UHFFFAOYSA-N CC(C)OCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound CC(C)OCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 BOKJIUOJQZULSG-UHFFFAOYSA-N 0.000 description 1
• XJGNXHPQJJVNNC-UHFFFAOYSA-N CC(C)c(cc1)ccc1NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CC(C)c(cc1)ccc1NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O XJGNXHPQJJVNNC-UHFFFAOYSA-N 0.000 description 1
• AVSVUSOOAINUHG-UHFFFAOYSA-O CC(C1)OC(C)CN1C(c(cc1)ccc1[NH2+]c1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)=O Chemical compound CC(C1)OC(C)CN1C(c(cc1)ccc1[NH2+]c1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)=O AVSVUSOOAINUHG-UHFFFAOYSA-O 0.000 description 1
• MYNXMCKIEYJDHL-UHFFFAOYSA-N CC(C1c2c(C3)cnc(Nc(cc4)ccc4S(O)(=O)=O)n2)C=CC=C1N(C)C3=O Chemical compound CC(C1c2c(C3)cnc(Nc(cc4)ccc4S(O)(=O)=O)n2)C=CC=C1N(C)C3=O MYNXMCKIEYJDHL-UHFFFAOYSA-N 0.000 description 1
• ODNHIJWMHNWASY-UHFFFAOYSA-N CC(CC1)CCC1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound CC(CC1)CCC1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 ODNHIJWMHNWASY-UHFFFAOYSA-N 0.000 description 1
• CQAFYEBMRUJNNJ-UHFFFAOYSA-N CC(CC1)CCN1C(c(cc1)ccc1NC(N(C)C=C1C2)N=C1c(ccc(Cl)c1)c1NC2=O)=O Chemical compound CC(CC1)CCN1C(c(cc1)ccc1NC(N(C)C=C1C2)N=C1c(ccc(Cl)c1)c1NC2=O)=O CQAFYEBMRUJNNJ-UHFFFAOYSA-N 0.000 description 1
• DZMFNECWNNILNV-UHFFFAOYSA-N CC(CC1)CCN1S(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)(=O)=O Chemical compound CC(CC1)CCN1S(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)(=O)=O DZMFNECWNNILNV-UHFFFAOYSA-N 0.000 description 1
• PZRJAZFKNOENJS-UHFFFAOYSA-N CC(CC=C1)C(N(C)C(C2)=O)=C1c1c2cnc(Nc(cc2)ccc2S(NCCN2CCCCC2)(=O)=O)n1 Chemical compound CC(CC=C1)C(N(C)C(C2)=O)=C1c1c2cnc(Nc(cc2)ccc2S(NCCN2CCCCC2)(=O)=O)n1 PZRJAZFKNOENJS-UHFFFAOYSA-N 0.000 description 1
• NWJLTIPSPDCTDQ-UHFFFAOYSA-N CC(CCC1)CN1S(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CC(CCC1)CN1S(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O NWJLTIPSPDCTDQ-UHFFFAOYSA-N 0.000 description 1
• WLXICZJDLPBVSY-UHFFFAOYSA-N CC(CCC1)N1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CC(CCC1)N1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O WLXICZJDLPBVSY-UHFFFAOYSA-N 0.000 description 1
• HNAHDHRLSWPRBB-UHFFFAOYSA-N CC(CN(C)C)NS(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CC(CN(C)C)NS(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O HNAHDHRLSWPRBB-UHFFFAOYSA-N 0.000 description 1
• FZUHKGHYVGAOSH-UHFFFAOYSA-N CC(COC)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CC(COC)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O FZUHKGHYVGAOSH-UHFFFAOYSA-N 0.000 description 1
• QQUAPVLFUKAINZ-UHFFFAOYSA-N CC(c1ccc[s]1)N(C)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CC(c1ccc[s]1)N(C)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O QQUAPVLFUKAINZ-UHFFFAOYSA-N 0.000 description 1
• MYFOHKPLKIRMCP-UHFFFAOYSA-N CC(c1ccccc1)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CC(c1ccccc1)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O MYFOHKPLKIRMCP-UHFFFAOYSA-N 0.000 description 1
• ZUVCDVKEQZQYDZ-UHFFFAOYSA-N CC1(Nc(cc2)ccc2C(NC(CN(C)C)c2ccccc2)=O)N=CC(CC(Nc2c3ccc(Cl)c2)=O)=C3N1 Chemical compound CC1(Nc(cc2)ccc2C(NC(CN(C)C)c2ccccc2)=O)N=CC(CC(Nc2c3ccc(Cl)c2)=O)=C3N1 ZUVCDVKEQZQYDZ-UHFFFAOYSA-N 0.000 description 1
• IWNKAUZQCLZUGD-UHFFFAOYSA-N CC1(c(ccc(C)c2)c2N2)NC(Nc(cc3)ccc3C(Nc3cc(OC)ccc3)=O)=NC=C1CC2=O Chemical compound CC1(c(ccc(C)c2)c2N2)NC(Nc(cc3)ccc3C(Nc3cc(OC)ccc3)=O)=NC=C1CC2=O IWNKAUZQCLZUGD-UHFFFAOYSA-N 0.000 description 1
• STPPRVQCRLGPCV-UHFFFAOYSA-N CC1N(C(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)c2ccccc2C1 Chemical compound CC1N(C(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)c2ccccc2C1 STPPRVQCRLGPCV-UHFFFAOYSA-N 0.000 description 1
• KNYPDAOGHRQSOZ-UHFFFAOYSA-N CC1N(CCCNc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)CCCC1 Chemical compound CC1N(CCCNc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)CCCC1 KNYPDAOGHRQSOZ-UHFFFAOYSA-N 0.000 description 1
• YVFXNOMCZPEJTG-UHFFFAOYSA-N CCC(COC)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CCC(COC)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O YVFXNOMCZPEJTG-UHFFFAOYSA-N 0.000 description 1
• ZRHXSXWDAANVIM-UHFFFAOYSA-N CCC(COC)NS(C(C=C1)=CC(C)C1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CCC(COC)NS(C(C=C1)=CC(C)C1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O ZRHXSXWDAANVIM-UHFFFAOYSA-N 0.000 description 1
• DNZYBLALWFONLS-UHFFFAOYSA-N CCCCN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CCCCN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O DNZYBLALWFONLS-UHFFFAOYSA-N 0.000 description 1
• KQKFBGAJFJFZHL-UHFFFAOYSA-N CCCCN(CCC#N)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CCCCN(CCC#N)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O KQKFBGAJFJFZHL-UHFFFAOYSA-N 0.000 description 1
• PTLGPEXMLVVXNJ-UHFFFAOYSA-N CCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound CCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 PTLGPEXMLVVXNJ-UHFFFAOYSA-N 0.000 description 1
• GUVFSGKAZJDTKA-UHFFFAOYSA-N CCN(C)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CCN(C)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O GUVFSGKAZJDTKA-UHFFFAOYSA-N 0.000 description 1
• LMFGZKVQKBHWFT-UHFFFAOYSA-N CCN(CC)c(cc1)ccc1NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CCN(CC)c(cc1)ccc1NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O LMFGZKVQKBHWFT-UHFFFAOYSA-N 0.000 description 1
• YNBHIIIASHQVAN-UHFFFAOYSA-N CCN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)=O Chemical compound CCN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)=O YNBHIIIASHQVAN-UHFFFAOYSA-N 0.000 description 1
• UFWRCPHGJCNCSZ-UHFFFAOYSA-N CCN(CCc1ccccn1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CCN(CCc1ccccn1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O UFWRCPHGJCNCSZ-UHFFFAOYSA-N 0.000 description 1
• BHAZCNAXVVQDKD-UHFFFAOYSA-N CCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound CCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 BHAZCNAXVVQDKD-UHFFFAOYSA-N 0.000 description 1
• PYQYKNKSZIOMSB-UHFFFAOYSA-N CCc1ccc(CN(C)C(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)cc1 Chemical compound CCc1ccc(CN(C)C(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)cc1 PYQYKNKSZIOMSB-UHFFFAOYSA-N 0.000 description 1
• NRFVHHYZROLOEH-UHFFFAOYSA-N CCc1ccccc1-c1ccc(CNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)[s]1 Chemical compound CCc1ccccc1-c1ccc(CNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)[s]1 NRFVHHYZROLOEH-UHFFFAOYSA-N 0.000 description 1
• 101150012716 CDK1 gene Proteins 0.000 description 1
• BZDQVVQXGMKVFG-UHFFFAOYSA-N CN(C(C1)O)c(cccc2)c2-c2c1cnc(Nc(cc1)ccc1S(N1CCOCC1)(=O)=O)n2 Chemical compound CN(C(C1)O)c(cccc2)c2-c2c1cnc(Nc(cc1)ccc1S(N1CCOCC1)(=O)=O)n2 BZDQVVQXGMKVFG-UHFFFAOYSA-N 0.000 description 1
• KNDMEYRQIZNKBR-UHFFFAOYSA-N CN(C)CCCN(C)S(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CN(C)CCCN(C)S(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)(=O)=O KNDMEYRQIZNKBR-UHFFFAOYSA-N 0.000 description 1
• BMUOCUCOMRXKJF-UHFFFAOYSA-N CN(C)c1cc(Nc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)ccc1 Chemical compound CN(C)c1cc(Nc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)ccc1 BMUOCUCOMRXKJF-UHFFFAOYSA-N 0.000 description 1
• RCTVMPQXYWHRNM-UHFFFAOYSA-N CN(C1CCNCC1)S(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CN(C1CCNCC1)S(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O RCTVMPQXYWHRNM-UHFFFAOYSA-N 0.000 description 1
• LNNJWEOAZCVFQY-UHFFFAOYSA-N CN(CC#C)S(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CN(CC#C)S(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)(=O)=O LNNJWEOAZCVFQY-UHFFFAOYSA-N 0.000 description 1
• NAEIDFLQNPQDJZ-UHFFFAOYSA-N CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O NAEIDFLQNPQDJZ-UHFFFAOYSA-N 0.000 description 1
• FTGMOKOJHZWZBZ-UHFFFAOYSA-N CN(CC1)CCN1S(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)(=O)=O Chemical compound CN(CC1)CCN1S(c(cc1)ccc1Nc1nc(-c(cccc2)c2N(C)C(C2)=O)c2cn1)(=O)=O FTGMOKOJHZWZBZ-UHFFFAOYSA-N 0.000 description 1
• SAHRDGVISZTIIC-UHFFFAOYSA-N CN(CCC1OCCO1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CN(CCC1OCCO1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O SAHRDGVISZTIIC-UHFFFAOYSA-N 0.000 description 1
• KJDAEMJPUDBHEL-UHFFFAOYSA-N CN(CCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)c1ccccc1 Chemical compound CN(CCCNc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)c1ccccc1 KJDAEMJPUDBHEL-UHFFFAOYSA-N 0.000 description 1
• VKDDHZFOSKXEFX-UHFFFAOYSA-N CN(Cc1nc(-c2ccccc2)n[o]1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound CN(Cc1nc(-c2ccccc2)n[o]1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O VKDDHZFOSKXEFX-UHFFFAOYSA-N 0.000 description 1
• KWDNRVMQWXMCEK-UHFFFAOYSA-N CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3C(NCc(cc3)ccc3Cl)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3C(NCc(cc3)ccc3Cl)=O)n1)C2=O KWDNRVMQWXMCEK-UHFFFAOYSA-N 0.000 description 1
• CHEWKEKFIVBOKI-UHFFFAOYSA-N CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3C(NCc3cc(F)ccc3F)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3C(NCc3cc(F)ccc3F)=O)n1)C2=O CHEWKEKFIVBOKI-UHFFFAOYSA-N 0.000 description 1
• XEWCWBHEQCGQFI-IBGZPJMESA-N CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3S(N3[C@H](COC)CCC3)(=O)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3S(N3[C@H](COC)CCC3)(=O)=O)n1)C2=O XEWCWBHEQCGQFI-IBGZPJMESA-N 0.000 description 1
• MQTLRNQCDHREEM-UHFFFAOYSA-N CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3S(NC3CCCC3)(=O)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3S(NC3CCCC3)(=O)=O)n1)C2=O MQTLRNQCDHREEM-UHFFFAOYSA-N 0.000 description 1
• BQXYICWSUSNWSV-UHFFFAOYSA-N CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3S(NCc3ncccc3)(=O)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc(Nc(cc3)ccc3S(NCc3ncccc3)(=O)=O)n1)C2=O BQXYICWSUSNWSV-UHFFFAOYSA-N 0.000 description 1
• HYZRHIHIMPBTSG-UHFFFAOYSA-O CN(c(cccc1)c1-c1c(C2)cnc([NH2+]c(cc3)ccc3C(O)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc([NH2+]c(cc3)ccc3C(O)=O)n1)C2=O HYZRHIHIMPBTSG-UHFFFAOYSA-O 0.000 description 1
• FLVOVAKYIDGPQH-UHFFFAOYSA-O CN(c(cccc1)c1-c1c(C2)cnc([NH2+]c(cc3)ccc3S(N3CCOCC3)(=O)=O)n1)C2=O Chemical compound CN(c(cccc1)c1-c1c(C2)cnc([NH2+]c(cc3)ccc3S(N3CCOCC3)(=O)=O)n1)C2=O FLVOVAKYIDGPQH-UHFFFAOYSA-O 0.000 description 1
• JRXDIFZGVHLTPS-UHFFFAOYSA-N CN(c1ccccc1)c1nc(-c(cc(cc2)Br)c2NC(C2)=O)c2cn1 Chemical compound CN(c1ccccc1)c1nc(-c(cc(cc2)Br)c2NC(C2)=O)c2cn1 JRXDIFZGVHLTPS-UHFFFAOYSA-N 0.000 description 1
• PUYBHOMOSHMTDN-UHFFFAOYSA-N CN1C(c(ccc(Cl)c2)c2NC(C2)=O)=C2C=NC1Nc(cc1)ccc1C(NC(CN1CCCC1)c1ccccc1)=O Chemical compound CN1C(c(ccc(Cl)c2)c2NC(C2)=O)=C2C=NC1Nc(cc1)ccc1C(NC(CN1CCCC1)c1ccccc1)=O PUYBHOMOSHMTDN-UHFFFAOYSA-N 0.000 description 1
• VMKRABXZXZUGKQ-UHFFFAOYSA-N CN1C(c(ccc(Cl)c2)c2NC(C2)=O)=C2C=NC1Nc(cc1)ccc1S(NC1CCCC1)(=O)=O Chemical compound CN1C(c(ccc(Cl)c2)c2NC(C2)=O)=C2C=NC1Nc(cc1)ccc1S(NC1CCCC1)(=O)=O VMKRABXZXZUGKQ-UHFFFAOYSA-N 0.000 description 1
• SSJKYJCUHNMZOQ-UHFFFAOYSA-N COC(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(N1CCOCC1)(=O)=O)n2 Chemical compound COC(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(N1CCOCC1)(=O)=O)n2 SSJKYJCUHNMZOQ-UHFFFAOYSA-N 0.000 description 1
• LMHOMMUMQHXZJL-UHFFFAOYSA-N COCCNS(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)O)c2cn1)(=O)=O Chemical compound COCCNS(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)O)c2cn1)(=O)=O LMHOMMUMQHXZJL-UHFFFAOYSA-N 0.000 description 1
• CWZFFZKFLMZRFY-UHFFFAOYSA-N COc(c(OC)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2N(CCCN)C(C2)=O)c2cn1 Chemical compound COc(c(OC)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2N(CCCN)C(C2)=O)c2cn1 CWZFFZKFLMZRFY-UHFFFAOYSA-N 0.000 description 1
• FNRMRKUDHUGJBI-UHFFFAOYSA-N COc(c(OC)c1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound COc(c(OC)c1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 FNRMRKUDHUGJBI-UHFFFAOYSA-N 0.000 description 1
• CJPJCUQONUJWQF-UHFFFAOYSA-N COc(c(OC)c1)ccc1Nc1ncc(CC(Nc2cc(C(N)=O)ccc2-2)=O)c-2n1 Chemical compound COc(c(OC)c1)ccc1Nc1ncc(CC(Nc2cc(C(N)=O)ccc2-2)=O)c-2n1 CJPJCUQONUJWQF-UHFFFAOYSA-N 0.000 description 1
• PCNTYLZFWBGQRA-UHFFFAOYSA-N COc(cc1)nc(OC)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound COc(cc1)nc(OC)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 PCNTYLZFWBGQRA-UHFFFAOYSA-N 0.000 description 1
• UDNYILBKAHXIMM-UHFFFAOYSA-N COc(ccc(Nc1ncc(CC(Nc2cc(C#CCN)ccc2-2)=O)c-2n1)c1)c1OC Chemical compound COc(ccc(Nc1ncc(CC(Nc2cc(C#CCN)ccc2-2)=O)c-2n1)c1)c1OC UDNYILBKAHXIMM-UHFFFAOYSA-N 0.000 description 1
• XWIZGSCTTCRBNJ-UHFFFAOYSA-N COc1ccc(C(CNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)N2CCOCC2)cc1 Chemical compound COc1ccc(C(CNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)N2CCOCC2)cc1 XWIZGSCTTCRBNJ-UHFFFAOYSA-N 0.000 description 1
• DIVNUTGTTIRPQA-UHFFFAOYSA-N COc1ccc(CN)cc1OC Chemical compound COc1ccc(CN)cc1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
• HLUHHPIOOWFWGG-UHFFFAOYSA-N CS(c1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound CS(c1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O HLUHHPIOOWFWGG-UHFFFAOYSA-N 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• RYYXMOZQJQIFHZ-UHFFFAOYSA-N Cc([n](C)nc1C)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound Cc([n](C)nc1C)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 RYYXMOZQJQIFHZ-UHFFFAOYSA-N 0.000 description 1
• HRKVWZPKIVMASD-UHFFFAOYSA-N Cc(cc(cc1)OC)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound Cc(cc(cc1)OC)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 HRKVWZPKIVMASD-UHFFFAOYSA-N 0.000 description 1
• NFNRXYLVILBATC-UHFFFAOYSA-N Cc(cc1)cc(Cl)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound Cc(cc1)cc(Cl)c1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 NFNRXYLVILBATC-UHFFFAOYSA-N 0.000 description 1
• GWKKYGFOKVDDBR-UHFFFAOYSA-N Cc1c(CNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)c(C)n[n]1C Chemical compound Cc1c(CNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)c(C)n[n]1C GWKKYGFOKVDDBR-UHFFFAOYSA-N 0.000 description 1
• WSVSBMVCWFHJRG-UHFFFAOYSA-N Cc1ccc(CCNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)cc1C Chemical compound Cc1ccc(CCNC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)cc1C WSVSBMVCWFHJRG-UHFFFAOYSA-N 0.000 description 1
• LZDYJSQWAJVMQE-UHFFFAOYSA-N Cc1ccc(CCNc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)cc1 Chemical compound Cc1ccc(CCNc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)cc1 LZDYJSQWAJVMQE-UHFFFAOYSA-N 0.000 description 1
• QFNIVWNZUARNKK-UHFFFAOYSA-N Cc1ccc(CN(C)C(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)cc1 Chemical compound Cc1ccc(CN(C)C(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)cc1 QFNIVWNZUARNKK-UHFFFAOYSA-N 0.000 description 1
• HDHFVVUPUUYGBB-UHFFFAOYSA-N Cc1ccc(CNS(c(cc2)ccc2NC(N(C)C=C2C3)N=C2c(cccc2)c2NC3=O)(OC)=O)[o]1 Chemical compound Cc1ccc(CNS(c(cc2)ccc2NC(N(C)C=C2C3)N=C2c(cccc2)c2NC3=O)(OC)=O)[o]1 HDHFVVUPUUYGBB-UHFFFAOYSA-N 0.000 description 1
• DTZBCQXRMZNIGP-UHFFFAOYSA-N Cc1ccnc(NC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)c1 Chemical compound Cc1ccnc(NC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)=O)c1 DTZBCQXRMZNIGP-UHFFFAOYSA-N 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920001076 Cutan Polymers 0.000 description 1
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
• 102000002427 Cyclin B Human genes 0.000 description 1
• 108010068150 Cyclin B Proteins 0.000 description 1
• 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
• 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
• 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
• 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101000684503 Homo sapiens Sentrin-specific protease 3 Proteins 0.000 description 1
• 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100325641 Mus musculus Aurka gene Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
• ULWYIVYFPIPRRK-UHFFFAOYSA-N N1C=CC=CC=C1.[S] Chemical compound N1C=CC=CC=C1.[S] ULWYIVYFPIPRRK-UHFFFAOYSA-N 0.000 description 1
• XSTXBUSWDMWEBG-AYNFRFQHSA-N N=C(c(cccc1)c1NC(C1)=O)/C1=C\NNNCc1cc(C(F)(F)F)cc(F)c1 Chemical compound N=C(c(cccc1)c1NC(C1)=O)/C1=C\NNNCc1cc(C(F)(F)F)cc(F)c1 XSTXBUSWDMWEBG-AYNFRFQHSA-N 0.000 description 1
• DIPOMUSKONMRTE-UHFFFAOYSA-N Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 DIPOMUSKONMRTE-UHFFFAOYSA-N 0.000 description 1
• 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JNXVVNURJBVHPP-UHFFFAOYSA-N O=C(C1)NCCN1S(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound O=C(C1)NCCN1S(c(cc1)ccc1Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1)(=O)=O JNXVVNURJBVHPP-UHFFFAOYSA-N 0.000 description 1
• FGPZUVQEAKKSKW-CYBMUJFWSA-N O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(NC1=CC[C@H]1OC(F)(F)F)n2 Chemical compound O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(NC1=CC[C@H]1OC(F)(F)F)n2 FGPZUVQEAKKSKW-CYBMUJFWSA-N 0.000 description 1
• RQVFWSSKGKZGCU-UHFFFAOYSA-N O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1I)n2 Chemical compound O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1I)n2 RQVFWSSKGKZGCU-UHFFFAOYSA-N 0.000 description 1
• KAYSFBLBNRVYBS-UHFFFAOYSA-N O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(NC1CCCCC1)(=O)=O)n2 Chemical compound O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(NC1CCCCC1)(=O)=O)n2 KAYSFBLBNRVYBS-UHFFFAOYSA-N 0.000 description 1
• OLQBSSKHNIIIEA-UHFFFAOYSA-N O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(NCC1CC1)(=O)=O)n2 Chemical compound O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(NCC1CC1)(=O)=O)n2 OLQBSSKHNIIIEA-UHFFFAOYSA-N 0.000 description 1
• VFMUSRLSHXSCHM-UHFFFAOYSA-N O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(Nc1ccccc1)(=O)=O)n2 Chemical compound O=C(C1)Nc(cc(cc2)Cl)c2-c2c1cnc(Nc(cc1)ccc1S(Nc1ccccc1)(=O)=O)n2 VFMUSRLSHXSCHM-UHFFFAOYSA-N 0.000 description 1
• YNZMEETYAVZOBG-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NC1CCC1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NC1CCC1)n2 YNZMEETYAVZOBG-UHFFFAOYSA-N 0.000 description 1
• MOPVOYZJWPZMHH-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NC1CCCC1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NC1CCCC1)n2 MOPVOYZJWPZMHH-UHFFFAOYSA-N 0.000 description 1
• SSGFRINNKVHIHW-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NCC1OCCC1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NCC1OCCC1)n2 SSGFRINNKVHIHW-UHFFFAOYSA-N 0.000 description 1
• AMDCANNPEPQZEF-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NCCCN1CCCC1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NCCCN1CCCC1)n2 AMDCANNPEPQZEF-UHFFFAOYSA-N 0.000 description 1
• HVDQXYPKMRTHLM-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NCCC[n]1cncc1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NCCC[n]1cncc1)n2 HVDQXYPKMRTHLM-UHFFFAOYSA-N 0.000 description 1
• MADKFGNAXMLWDV-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NCCOc1ccccc1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NCCOc1ccccc1)n2 MADKFGNAXMLWDV-UHFFFAOYSA-N 0.000 description 1
• JMMPIYTWBXGTJY-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NCc1cccc(C(F)(F)F)c1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NCc1cccc(C(F)(F)F)c1)n2 JMMPIYTWBXGTJY-UHFFFAOYSA-N 0.000 description 1
• GAIPYILPDJZNAP-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NCc1ccccc1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NCc1ccccc1)n2 GAIPYILPDJZNAP-UHFFFAOYSA-N 0.000 description 1
• CLEGIPHHJAFDFE-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(NI)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(NI)n2 CLEGIPHHJAFDFE-UHFFFAOYSA-N 0.000 description 1
• XDYWTYJKLZWBMQ-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1)ccc1N1CCOCC1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1)ccc1N1CCOCC1)n2 XDYWTYJKLZWBMQ-UHFFFAOYSA-N 0.000 description 1
• YRMRTOQELHDSHR-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1)ccc1S(NCCc1ccc[s]1)(=O)=O)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1)ccc1S(NCCc1ccc[s]1)(=O)=O)n2 YRMRTOQELHDSHR-UHFFFAOYSA-N 0.000 description 1
• FJRQSWYYDYNBKO-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1)ccc1S(NCc(cc1)ccc1Cl)(=O)=O)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1)ccc1S(NCc(cc1)ccc1Cl)(=O)=O)n2 FJRQSWYYDYNBKO-UHFFFAOYSA-N 0.000 description 1
• KSYQQVWRAUEGEU-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1Cl)ccc1F)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(cc1Cl)ccc1F)n2 KSYQQVWRAUEGEU-UHFFFAOYSA-N 0.000 description 1
• HCTLHBCLENDNRJ-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(nc1)ccc1Cl)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc(nc1)ccc1Cl)n2 HCTLHBCLENDNRJ-UHFFFAOYSA-N 0.000 description 1
• OTUUKSZMKNCJLZ-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc1ccc(C(F)(F)F)cc1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc1ccc(C(F)(F)F)cc1)n2 OTUUKSZMKNCJLZ-UHFFFAOYSA-N 0.000 description 1
• XEQNTUPAXPXSMM-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc1ccc3OCCOc3c1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc1ccc3OCCOc3c1)n2 XEQNTUPAXPXSMM-UHFFFAOYSA-N 0.000 description 1
• DQWCUVFEJNDUEU-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc1ncccn1)n2 Chemical compound O=C(C1)Nc(cccc2)c2-c2c1cnc(Nc1ncccn1)n2 DQWCUVFEJNDUEU-UHFFFAOYSA-N 0.000 description 1
• WRZRZYXLNTXVGU-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)N(CC1)CCC1N1CCCC1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)N(CC1)CCC1N1CCCC1 WRZRZYXLNTXVGU-UHFFFAOYSA-N 0.000 description 1
• XNWFCBXAQFDVCX-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NC1CCCCCCC1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NC1CCCCCCC1 XNWFCBXAQFDVCX-UHFFFAOYSA-N 0.000 description 1
• CPAUCZBHTAWVQW-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCC(c1cccnc1)N1CCCC1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCC(c1cccnc1)N1CCCC1 CPAUCZBHTAWVQW-UHFFFAOYSA-N 0.000 description 1
• QXQSEWNWHBKILL-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCCOc1ccccc1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCCOc1ccccc1 QXQSEWNWHBKILL-UHFFFAOYSA-N 0.000 description 1
• MROQLKMYGKFGOZ-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCCc(cccc1)c1F Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCCc(cccc1)c1F MROQLKMYGKFGOZ-UHFFFAOYSA-N 0.000 description 1
• GFNVDCVTEMHODY-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCc(cc1)ccc1F Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCc(cc1)ccc1F GFNVDCVTEMHODY-UHFFFAOYSA-N 0.000 description 1
• LJJQQXVVAUHZDA-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCc1c[s]cc1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCc1c[s]cc1 LJJQQXVVAUHZDA-UHFFFAOYSA-N 0.000 description 1
• OWMPZDJRYRCIDN-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCc1nc2ccccc2[nH]1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)NCc1nc2ccccc2[nH]1 OWMPZDJRYRCIDN-UHFFFAOYSA-N 0.000 description 1
• WPKGJHUSUCHAHE-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)Nc1ccnc(Cl)c1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)Nc1ccnc(Cl)c1 WPKGJHUSUCHAHE-UHFFFAOYSA-N 0.000 description 1
• VONQGTDVPRXSFZ-UHFFFAOYSA-N O=C1N(CCCNS(c(cc2)ccc2Nc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)(=O)=O)CCC1 Chemical compound O=C1N(CCCNS(c(cc2)ccc2Nc2nc(-c(cccc3)c3NC(C3)=O)c3cn2)(=O)=O)CCC1 VONQGTDVPRXSFZ-UHFFFAOYSA-N 0.000 description 1
• FKKMPQBOUGSCIY-UHFFFAOYSA-N O=CN(CCC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O Chemical compound O=CN(CCC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)=O FKKMPQBOUGSCIY-UHFFFAOYSA-N 0.000 description 1
• STHSZNFNJBHIIY-UHFFFAOYSA-N O=CN(CCC1)CCN1S(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O Chemical compound O=CN(CCC1)CCN1S(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(=O)=O STHSZNFNJBHIIY-UHFFFAOYSA-N 0.000 description 1
• SLNFHWIYCHAKTK-UHFFFAOYSA-N OC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2N(c2ccccc2)C(C2)=O)c2cn1)=O Chemical compound OC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2N(c2ccccc2)C(C2)=O)c2cn1)=O SLNFHWIYCHAKTK-UHFFFAOYSA-N 0.000 description 1
• FQSFOPLPKGLDFN-UHFFFAOYSA-N OCC(Cc(cc1)ccc1Cl)Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 Chemical compound OCC(Cc(cc1)ccc1Cl)Nc1nc(-c(cccc2)c2NC(C2)=O)c2cn1 FQSFOPLPKGLDFN-UHFFFAOYSA-N 0.000 description 1
• GZARWGNMTGDFNN-UHFFFAOYSA-N OCCc1cccc(Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)c1 Chemical compound OCCc1cccc(Nc2nc(-c(ccc(Cl)c3)c3NC(C3)=O)c3cn2)c1 GZARWGNMTGDFNN-UHFFFAOYSA-N 0.000 description 1
• JNCHKWJQXATJNX-UHFFFAOYSA-N OS(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(Nc1ccc2[nH]ccc2c1)=O Chemical compound OS(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2NC(C2)=O)c2cn1)(Nc1ccc2[nH]ccc2c1)=O JNCHKWJQXATJNX-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
• 239000007868 Raney catalyst Substances 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 102100023645 Sentrin-specific protease 3 Human genes 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 240000006474 Theobroma bicolor Species 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
• 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
• HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
• HVQLJMQNUJXZCF-UHFFFAOYSA-O [N+](=O)([O-])[O-].C(#N)CC=1C=C(C=CC1)NC(=[NH2+])N Chemical compound [N+](=O)([O-])[O-].C(#N)CC=1C=C(C=CC1)NC(=[NH2+])N HVQLJMQNUJXZCF-UHFFFAOYSA-O 0.000 description 1
• XYWDNDBIORLANZ-UHFFFAOYSA-O [N+](=O)([O-])[O-].CC=1C=C(C=CC1C)NC(=[NH2+])N Chemical compound [N+](=O)([O-])[O-].CC=1C=C(C=CC1C)NC(=[NH2+])N XYWDNDBIORLANZ-UHFFFAOYSA-O 0.000 description 1
• IOCLLUMCPYPTOG-UHFFFAOYSA-O [N+](=O)([O-])[O-].IC1=CC=C(C=C1)NC(=[NH2+])N Chemical compound [N+](=O)([O-])[O-].IC1=CC=C(C=C1)NC(=[NH2+])N IOCLLUMCPYPTOG-UHFFFAOYSA-O 0.000 description 1
• CVSDXLMGZQZLJW-UHFFFAOYSA-O [N+](=O)([O-])[O-].IC=1C=C(C=CC1)NC(=[NH2+])N Chemical compound [N+](=O)([O-])[O-].IC=1C=C(C=CC1)NC(=[NH2+])N CVSDXLMGZQZLJW-UHFFFAOYSA-O 0.000 description 1
• HBOPVJJZFWIXOS-UHFFFAOYSA-M [Na][Zn]Cl Chemical compound [Na][Zn]Cl HBOPVJJZFWIXOS-UHFFFAOYSA-M 0.000 description 1
• COGNCXJCCDGTDV-UHFFFAOYSA-N [O].N1C=CC=CC=C1 Chemical compound [O].N1C=CC=CC=C1 COGNCXJCCDGTDV-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• ZMQBBPRAZLACCW-UHFFFAOYSA-N acetic acid;dichloromethane Chemical compound ClCCl.CC(O)=O ZMQBBPRAZLACCW-UHFFFAOYSA-N 0.000 description 1
• CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 238000001467 acupuncture Methods 0.000 description 1
• 150000001263 acyl chlorides Chemical class 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 208000030002 adult glioblastoma Diseases 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 150000001503 aryl iodides Chemical class 0.000 description 1
• 238000006254 arylation reaction Methods 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 150000003851 azoles Chemical class 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
• 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000012928 buffer substance Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229950005953 camsilate Drugs 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• BGVZTPNHLAGGCF-UHFFFAOYSA-O carbamimidoyl-(3,5-dimethoxyphenyl)azanium;nitrate Chemical compound [O-][N+]([O-])=O.COC1=CC(OC)=CC([NH+]=C(N)N)=C1 BGVZTPNHLAGGCF-UHFFFAOYSA-O 0.000 description 1
• FKPMGXJMACMVBU-UHFFFAOYSA-O carbamimidoyl-(3,5-dimethylphenyl)azanium nitrate Chemical compound [O-][N+]([O-])=O.CC1=CC(C)=CC([NH2+]C(N)=N)=C1 FKPMGXJMACMVBU-UHFFFAOYSA-O 0.000 description 1
• MGWMPUKTQNROOY-UHFFFAOYSA-O carbamimidoyl-[3-(2-hydroxyethyl)phenyl]azanium;nitrate Chemical compound [O-][N+]([O-])=O.NC(N)=[NH+]C1=CC=CC(CCO)=C1 MGWMPUKTQNROOY-UHFFFAOYSA-O 0.000 description 1
• NZXRFGHWGPEIEZ-UHFFFAOYSA-N carbamimidoylazanium;2,2,2-trifluoroacetate Chemical compound NC(N)=N.OC(=O)C(F)(F)F NZXRFGHWGPEIEZ-UHFFFAOYSA-N 0.000 description 1
• GZBKCIJLEXDUOL-UHFFFAOYSA-N carbamimidoylazanium;hydron;sulfite Chemical compound NC(N)=N.OS(O)=O GZBKCIJLEXDUOL-UHFFFAOYSA-N 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 208000015100 cartilage disease Diseases 0.000 description 1
• 101150069072 cdc25 gene Proteins 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 210000003793 centrosome Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 238000005660 chlorination reaction Methods 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 230000024321 chromosome segregation Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
• 239000004913 cyclooctene Substances 0.000 description 1
• BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000009849 deactivation Effects 0.000 description 1
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
• 238000006114 decarboxylation reaction Methods 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 239000000645 desinfectant Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 210000002969 egg yolk Anatomy 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229950005627 embonate Drugs 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 150000002084 enol ethers Chemical class 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 239000012259 ether extract Substances 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
• IXZFDJXHLQQSGQ-UHFFFAOYSA-N ethyl 4-chloro-4-oxobutanoate Chemical compound CCOC(=O)CCC(Cl)=O IXZFDJXHLQQSGQ-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002194 fatty esters Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229930182478 glucoside Natural products 0.000 description 1
• 150000008131 glucosides Chemical class 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
• CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• XKPJKVVZOOEMPK-UHFFFAOYSA-M lithium;formate Chemical compound [Li+].[O-]C=O XKPJKVVZOOEMPK-UHFFFAOYSA-M 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000011645 metastatic carcinoma Diseases 0.000 description 1
• OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• SXWBLVFGECGROC-UHFFFAOYSA-N methyl 4-(diaminomethylideneamino)benzoate;hydrochloride Chemical class Cl.COC(=O)C1=CC=C(NC(N)=N)C=C1 SXWBLVFGECGROC-UHFFFAOYSA-N 0.000 description 1
• 229940102398 methyl anthranilate Drugs 0.000 description 1
• SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 1
• 239000012022 methylating agents‎ Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
• 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 230000004987 nonapoptotic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 201000002628 peritoneum cancer Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000003209 petroleum derivative Substances 0.000 description 1
• 210000004332 phalangeal cell Anatomy 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 150000003053 piperidines Chemical class 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 235000019633 pungent taste Nutrition 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 238000007347 radical substitution reaction Methods 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 238000007670 refining Methods 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 239000011435 rock Substances 0.000 description 1
• 238000009666 routine test Methods 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 239000011775 sodium fluoride Substances 0.000 description 1
• 235000013024 sodium fluoride Nutrition 0.000 description 1
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000012177 spermaceti Substances 0.000 description 1
• 229940084106 spermaceti Drugs 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
• JOKPITBUODAHEN-UHFFFAOYSA-N sulfanylideneplatinum Chemical compound [Pt]=S JOKPITBUODAHEN-UHFFFAOYSA-N 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
• 229960000658 sumatriptan succinate Drugs 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
• POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
• CSOJECDGWHHWRS-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylcarbamothioyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=S)NC(=O)OC(C)(C)C CSOJECDGWHHWRS-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 239000012745 toughening agent Substances 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 238000002525 ultrasonication Methods 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 206010055031 vascular neoplasm Diseases 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1